Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Levels of C3 in patients with severe, morbid and extreme obesity: its relationship to insulin resistance and different cardiovascular risk factors

International Journal of Obesity volume 31, pages 927–932 (2007)Cite this article

Abstract

Objective:

Increased C3 has been related to body mass index (BMI) and insulin resistance, although there are not sufficient studies in subjects with morbid obesity. The purpose of this study was to evaluate the levels of C3 as a function of the BMI in subjects of both sexes, with severe, morbid and extreme obesity, and their possible relationship to insulin resistance or associated diseases such as diabetes, hypertension and dyslipidemia.

Subjects:

The study included a total of 316 patients (110 men and 206 women) with severe obesity (17.1%), morbid obesity (54.4%) and extreme obesity (28.4%), with an average BMI of 46.70±7.37 kg/m2.

Measurements:

The glucose and insulin levels were determined baseline, and 2 h after a 75 g of oral glucose load. The homeostasis model of assessment for insulin resistance (HOMA-IR) was calculated. A lipid profile (total cholesterol, triglycerides, high-density lipoprotein cholesterol, apolipoprotein AI and apolipoprotein B100) was obtained and C3 levels determined by nephelometry.

Results:

When distributing the patients by quartiles of BMI, we found a progressive increase in the levels of C3, and no significant differences in the rest of analytical variables studied were found; the mean values of C3 were 127.78±29.7 mg/dl.

A significant correlation was found between C3 and the BMI (r=0.263, P<0.001), baseline insulin (r=0.237, P=0.001) and HOMA-IR (r=0.237, P=0.001). High blood pressure was found in 111 patients, type 2 diabetes in 74 patients and dyslipidemia in 139 cases. When distributing the levels of C3 according to the number of associated risk factors (hypertension, diabetes and dyslipidemia), we found significant differences between these patients and those who presented no associated diseases (P<0.01).

Conclusion:

A relationship between C3 and the progressive increase of BMI in subjects with severe, morbid or extreme obesity was established. This increase in C3 was closely related to insulin levels and the values for HOMA-IR. Furthermore, we also found an increase in C3 as more diseases related to insulin resistance, such as diabetes, hypertension and dyslipidemia, were associated with the obesity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Hansson GK . Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685–1695.

    Article  CAS  Google Scholar 

  2. Gabrielsson BG, Johansson JM, Lonn M, Jernas M, Olbers T, Peltonen M et al. High expression of complement components in omental adipose tissue in obese men. Obes Res 2003; 11: 699–708.

    Article  CAS  Google Scholar 

  3. Koistinen HA, Vidal H, Karonen SL, Dusserre E, Vallier P, Koivisto VA et al. Plasma acylation stimulating protein concentration and subcutaneous adipose tissue C3 mRNA expression in nondiabetic and type 2 diabetic men. Arterioscler Thromb Vasc Biol 2001; 21: 1034–1039.

    Article  CAS  Google Scholar 

  4. Muscari A, Massarelli G, Bastagli L, Poggiopollini G, Tomassetti V, Volta U et al. Relationship between serum C3 levels and traditional risk factors for myocardial infarction. Acta Cardiol 1998; 53: 345–354.

    CAS  Google Scholar 

  5. Muscari A, Massarelli G, Bastagli L, Poggiopollini G, Tomassetti V, Drago G et al. Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men. Eur Heart J 2000; 21: 1081–1090.

    Article  CAS  Google Scholar 

  6. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW . C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972–978.

    Article  CAS  Google Scholar 

  7. Sociedad Española para el Estudio de la Obesidad (SEEDO). SEEDO 2000 consensus for the evaluation of overweight and obesity and the assessment of obesity management. Med Clin (Barc) 2000; 115: 587–597.

  8. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004; 328: 634–640.

    Article  Google Scholar 

  9. Standards of Medical Care in Diabetes. American Diabetes Association. Diabetes Care 2005; 28 (Suppl 1): S4–S36.

  10. Allan CC, Poon LS, Chan CSG, Richmond W, Fu PC . Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470–475.

    Google Scholar 

  11. Bucolo G, David H . Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973; 19: 476–482.

    CAS  PubMed  Google Scholar 

  12. Sugiuchi H, Uji Y, Okabe H, Irie T, Uekama K, Kayahara N et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem 1995; 41: 717–723.

    CAS  PubMed  Google Scholar 

  13. Friedewald WT, Levy RI, Fredricson DS . Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.

    CAS  Google Scholar 

  14. Maciejko JJ, Levinson SS, Markyvech L, Smith MP, Blevins RD . New assay of apolipoproteins A-I and B by rate nephelometry evaluated. Clin Chem 1987; 33: 2065–2069.

    CAS  PubMed  Google Scholar 

  15. Sternberg JC . A rate nephelometer for measuring specific proteins by inmunoprecipitatin reactions. Clin Chem 1977; 23: 1456–1464.

    CAS  PubMed  Google Scholar 

  16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC . Homeostasis model assessment: insulin resistance ad β-cell function from fasting plasma glucose ad insulin concentration in man. Diabetologia 1985; 28: 412–419.

    Article  CAS  Google Scholar 

  17. Mohammed-Ali V, Pinkey JH, Coppack SW . Adipose tissue as an endocrine and paracrine organ. Int J Obes 1998; 22: 1145–1158.

    Article  Google Scholar 

  18. Sniderman AD, Cianflone K, Arner P, Summers LKM, Frayn KN . The adipocyte, fatty acid trapping, and atherogenesis. Arterioscler Thromb Vasc Biol 1998; 18: 147–151.

    Article  CAS  Google Scholar 

  19. Cianflone K . Acylation stimulating protein and the adipocyte. J Endocrinol 1997; 155: 203–206.

    Article  CAS  Google Scholar 

  20. Weyer C, Tataranni PA, Pratley RE . Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration. Diabetes Care 2000; 23: 779–785.

    Article  CAS  Google Scholar 

  21. Figueredo A, Ibarra JL, Bagazgoitia J, Rodriguez A, Molino AM, Fernandez-Cruz A et al. Plasma C3d levels and ischemic heart disease in type II diabetes. Diabetes Care 1993; 16: 445–449.

    Article  CAS  Google Scholar 

  22. Mantov S, Raev D . Additive effects of diabetes and systemic hypertension on the immune mechanisms of atherosclerosis. Int J Cardiol 1996; 56: 145–148.

    Article  CAS  Google Scholar 

  23. Hansson GK, Jonasson L, Seifert PS, Stemme S . Immune mechanisms in atherosclerosis. Arteriosclerosis 1989; 9: 567–578.

    Article  CAS  Google Scholar 

  24. Cianflone K, Lu H, Smith J, Yu W, Wang H . Adiponectin, acylation stimulating protein and complement C3 are altered in obesity in very young children. Clin Endocrinol 2005; 62: 567–572.

    Article  CAS  Google Scholar 

  25. Hotamisligil GS, Spiegelman BM . Tumor necrosis factor α: a key component of the obesity–diabetes link. Diabetes 1994; 43: 1271–1278.

    Article  CAS  Google Scholar 

  26. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS et al. Subcutaneous adipose tissue release IL6 but no TNF-α in vivo. J Clin Endo Metab 1997; 82: 4196–4200.

    CAS  Google Scholar 

  27. Ylitalo K, Porkka KVK, Mari S, Nuotio I, Suurinkeroinen L, Vakkilainen J et al. Serum complement and familial combined hyperlipidemia. Atherosclerosis 1997; 129: 271–277.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology Service, Dr Peset University Hospital, Valencia, Spain

    A Hernández-Mijares, M M Jarabo-Bueno, A López-Ruiz, E Solá-Izquierdo & C Morillas-Ariño

  2. Department of Medicine, University of Valencia, Valencia, Spain

    A Hernández-Mijares, E Solá-Izquierdo & C Morillas-Ariño

  3. Clinical Analysis Service, Castellón General Hospital, Valencia, Spain

    M L Martínez-Triguero

Authors
  1. A Hernández-Mijares
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M M Jarabo-Bueno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A López-Ruiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Solá-Izquierdo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Morillas-Ariño
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M L Martínez-Triguero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Hernández-Mijares.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hernández-Mijares, A., Jarabo-Bueno, M., López-Ruiz, A. et al. Levels of C3 in patients with severe, morbid and extreme obesity: its relationship to insulin resistance and different cardiovascular risk factors. Int J Obes 31, 927–932 (2007). https://doi.org/10.1038/sj.ijo.0803543

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0803543

Keywords

This article is cited by

Search

Advanced search

Quick links